Field-tested ideas
on brand revitalization.
Frameworks, case studies, and economic models from the trenches of mature and tail-end brand growth in India.
Visit the Medstry BlogWhy 70% of pharma brands stagnate after year 7 — and how to fix it.
A practical framework for identifying mature and tail-end brands that still have growth runway in extra-urban India, plus the channel levers that reignite prescription velocity.
The Delta Field Force economics: a CFO's view.
Modeling 40–50% OPEX reduction and the breakeven curve vs traditional in-house field deployment — with worked examples across portfolio sizes.
₹168 Cr unlocked: revitalizing a Top-10 pharma division.
How a 3D Phygital rollout turned a 70% mature & tail-end portfolio into the division's growth engine in 18 months — and the operational playbook behind it.
Channel-led brand growth in Tier 2–4 India.
Availability is God. A field manual for building chemist relationships and channel velocity in markets traditional reps rarely service.
Mantrepreneurship: building an entrepreneurial pharma field force.
How Medstry hires, trains, and retains young pharmacy graduates from Tier 2–3 cities — and why that talent edge matters for your mature brands.
India Market Entry for MNCs: the extra-urban playbook.
Why a direct urban-only entry strategy leaves 25–40% of Indian pharma value on the table — and how to avoid the mistake.
Our latest perspectives on mature-brand growth — delivered first.
Drop us a note and we'll send fresh case studies and frameworks as they publish.